Clinical Trial Supply (CTS) Market Intelligence

COVID 19 impact on Clinical Trial Supply (CTS) market

  • Pharma companies have started to halt their clinical trials except COVID-19 related drugs and vaccines. This initiative is taken up to free medical personals and to reduce risk on results of other clinical trials.
  • If COVID-19 impact increases, the on-going trials might also move to a halt in forthcoming quarters resulting in drop of revenue and increased R&D budget

Are your suppliers secure from the covid-19 impact?

Check Now

Report Coverage

  • Technological Trends
  • Supplier Analysis
  • Supplier Profiling
  • Best Practices

Market Size

Global Market Size

$1,039 Mn

CAGR

7.2 Percent

Table of contents

  1. Clinical Trial Supply Executive Summary
  1. Clinical Trial Supply Market Analysis
  2. CTS Market Overview
  3. Drivers and Constraints
  4. Market trends
  5. Porter’s Five Forces Analysis
  6. Category Segmentation
  1. Clinical Trial Supply Best Practices
  2. CTS Cost Break up Analysis
  3. Best Practices
  4. Comparator Sourcing Market
  1. Clinical Trial Supply Supply Market Overview
  2. Supplier Analysis
  3. Supplier Analyisis comparator Sourcing
  4. Supplier Profiling
  5. Supplier Development
  1. Clinical Trial Supply Market Insights
  2. Digitalization
  3. Others
  4. Logistics
  5. Turnaround Time

Want a more detailed personalised report?

Global Clinical Trial Supply Market Outlook

  • Clinical trials are a very important activity in the Pharma R&D sector. Clinical Research Organizations are involved in carrying out trials of new drugs in the market. A CRO or a contract research organization is a Clinical Services company that offers trial management services to pharma companies. Outsourcing is beneficial for pharma companies that can organize Large Scale Clinical trials.
  • An SMO or site management organization helps CROs or pharma companies in conducting Phase II- III trials. These companies need supplies to effectively carry out clinical trials. This clinical trial supply market report can help them understand the market effectively. This would help them plan and manage clinical trial activities in an effective way.
  • The global clinical trial supplies market is expected to grow at a CAGR of 7.2 percent during 2015-2022. This will be driven by the growth in the biologics pipeline, growth of clinical trial footprint in the emerging markets (Brazil, China, India, Russia, South Korea), and increase in adoption of comparator studies.
  • The global clinical trial supply and logistics market is expected to grow at a CAGR of 7.1 percent. The market was estimated at $14.84 billion in 2016 and is expected to be valued at $21.5 billion in 2021.
  • The global clinical trial supply market was expected to grow at a CAGR of 7.2 percent and was estimated to reach $1.2 billion by 2020 from $904.3 million in 2015. By 2025, it is estimated that the clinical trial supplies market would reach $2.5 billion. 
  • Clinical Trial Supplies Market Growth: CAGR Growth Rate: 7.2 percent by 2022. The 2017 Market Value was $1,039 Million.
  • The clinical trial supplies market driven by the growth in Pharma R&D expenditure in pharmaceutical and biopharmaceutical companies. The clinical trial supplies market has become globalised because of better regulations.
  • North America accounts for about 40–45 percent of the clinical trial supplies. Major CROs and biopharmaceutical companies have their hub in this region because of a higher number of large scale pharma R&D clinical trials conducted in these regions.
  • The clinical trial supply market has different segments like logistics, packaging, labeling, manufacturing, and solutions. Of these different segments, the logistics segment would dominate the market. The globalization of clinical trials and the requirement for temperature-sensitive shipping of products has resulted in a greater requirement for logistics in clinical supply.
  • Clinical trials are carried out in different phases. Phase III trials are expected to grow at the highest rate. Since this phase of the trial takes the most time and involves the most expenses, the need for supplies is the highest here.

clinical trial supply market

Clinical Trial Supplies Market Trends

  • Clinical trials are studies to test a drug or a medical intervention on people as a part of drug or treatment development. This is the main means of finding out if the new development is safe and effective by testing it on actual people. It is also used to determine if there are side effects from any of the treatments.
  • These clinical trials are usually performed by outsourcing to Clinical Research Organizations (CRO). Clinical Trials usually start with Phase I trials on a small group to determine the safety and required dosage. This is usually in-house or tested locally.
  • The Phase II- III trials are usually large scale clinical trials. Phase II is usually to test the effectiveness, safety, and side effects. Phase II uses 100 to 300 participants. Phase III is on a larger scale up to around 3000 participants and tests the drug on different populations, with other drug combinations in addition to safety and efficacy. Phase III also takes a longer period of time to study the drug.
  • Phase IV of clinical trials is a period after the approval of the treatment when it continues to be monitored for long term side effects and other safety issues.
  • The clinical trial supplies industry is growing internationally and clinical trials are increasingly being performed across country borders as the safety laws that govern them are becoming more homogenous worldwide. They are managed by a Site Management Organization or SMO. Trials are monitored by an Independent Safety Monitor (ISM)

Drivers and Constraints

Drivers

  • Stringent Regulatory Environment: FDA and other regulatory authorities have increased stringency of quality, storage, packaging and labeling, distribution, and recall of ancillary products. Companies now source ancillary products at different levels, like central sourcing and regional sourcing.
  • Globalization of Clinical Trials: Due to the globalization of clinical trials, pharma companies are conducting clinical trials, especially phase III clinical trials in distinct geographies, including the fast-growing Eastern Europe, China, Korea, and Taiwan. This has led to an increase in planning and sourcing ancillary materials.
  • R&D Investments: Increase in R&D investments and government support increased the scope to conduct more research.
  • A major driver for the clinical trial supply market is the increased expenditure on R&D by biopharmaceutical companies, as well as the pharmaceutical companies.
  • The clinical trial supply market has seen rapid growth due to the COVID-19 situation. The demand for a vaccine for the coronavirus has seen a spurt in clinical trials across the world. Millions of people across the world need to be vaccinated, prior to which trials have to be completed. The clinical trial supply trends have seen a boost due to this situation. Clinical trials are being carried out not just for vaccines but even for medicines to treat COVID-19 and associated symptoms. This is going to be a major driver for the clinical trial market.

Constrains

  • High Waste and Overage: Clinical trials are experiencing a very high level, approximately 150–200 percent of clinical supply waste leads to unwanted cost escalation and high inventory. This impacts the use of internal resources within pharma and biotech companies.
  • Interactive Response Technology: Regulatory environment in many countries is very dynamic for some time and change comes very fast. This, along with a high initial cost for installing IRT, proves to be an obstacle in the path of integrating Clinical Ancillaries with Interactive Response Technology (IRT), and most of the work is done on a manual basis using excel sheets.
  • North America has well-established CROs. The increasing investments in R&D by pharmaceutical and biopharmaceutical companies are the major factors responsible for North America’s share in the clinical trial supplies industry.
  • The Asia Pacific CTS market has a larger patient population. The rules and regulations that govern patient recruitment are less strict and this is driving the upward clinical trial supplies market trends.

Regulatory Trends

Continuous change in regulations and regional governing bodies will affect the importing of clinical trial supplies. Utilizing an import broker to overcome regional difficulties like compliance with import/export regulations for shipments of clinical trial supplies will benefit pharma in the smooth running of clinical trials.

BREXIT

With the lack of regulatory clarity between the UK and the rest of EU countries, it is inevitable for pharma to plan and execute long-term clinical strategies till EMA re-establishes its base.

Post BREXIT, non-EU countries cannot import the clinical trial supplies into the UK to distribute throughout the EU and it will be critical for EU-based QP to work with UK-based QP for smooth running of trials.

EMA has developed A European One Health Action Plan against AMR which contains initiatives like:

  • Making the EU the best practice region in terms of fighting Antimicrobial Resistance (AMR) growth
  • Boosting research, development, and innovation
  • Shaping the global agenda by making the EU more influential on AMR internationally

Regulation 536/2014 (CTR)

Clinical Trial Regulation (Regulation 536/2014, CTR), which can provide a centralized database and entry point for information related to EU clinical trial data submissions was not available before 2019 due to delay in establishing the IT infrastructure because of no clarity in EMA shift from the UK.

Clinical trial authorization for investigator-initiated studies

Additional Clinical Trial Authorization (CTA) should be submitted for Investigator-Initiated Clinical Studies (IIS) - Investigational Medicinal Product Dossier (IMPD) information, Summary of Product Characteristics (SPC) for marketed drugs and if non-authorized products are used, Cross-reference-letter by the manufacturer referencing to an existing IMPD available from the Health Authorities should be submitted.

Market Overview

Strategic partnership with features like price benchmarking, spend consolidation, and demand forecasting will bring the buyer and supplier in the clinical trial services industry to equilibrium in the next 2-3 years.

The core providers of clinical trial services provide the most comprehensive range of services dedicated to the pharmaceutical industry. E.g., Fisher, Marken, Parexel, Catalent, etc.

The information on clinical trial sourcing shows that majority of clinical trial supply services are outsourced. Secondary packaging, shipping, and distribution account for the larger portion of the outsourced services.

The comparator sourcing for clinical trials has a market share as follows: Myoderm + Clinigen + Fisher Clinical - 35% and Others - 65%.

Most suppliers of comparator trial drugs are relatively small and tend to be nationally focused or part of larger organizations (usually wholesalers). The margin charged by the suppliers can vary based on the complexity of the supply chain. Supply market consolidation can increase the market share of top suppliers.

The key players in the clinical trial supply market are Thermo Fisher Scientific Inc., Sharp Packaging Services, Biocair, O&M Movianto, Parexel International Corporation, Almac Group, and KLIFO A/S.

Why You Should Buy This Report

The report provides you the CTS market overview, drivers and constraints, regulatory and technological trends, etc. It offers Porter’s five forces analysis of the global clinical trial supplies market. The report gives information about comparator sourcing for clinical trials, CTS supplier analysis, supplier profiling, etc. It gives an insight into the clinical trial services market (digitization, logistics, etc.)

 

Clinical Trial Supply Market Frequently Asked Questions

  1. What factors drive the growth of the global clinical trial supply market?
  2. According to Beroe’s report, the clinical trial supply market will be driven by the following factors: Growth in biologics pipeline Growth of clinical trials footprint in the emerging markets (Brazil, China, Russia, India, South Korea) Increase in adoption of comparator studies
  1. What is the expected growth rate of the clinical trial supply market?
  2. As per Beroe’s analysis, the global market for clinical trial supplies is expected to grow at a CAGR of 7.2 percent and reach a valuation of $1.2 billion by 2020 escalating from $904.3 million in 2015.
  1. What market share does North America captures w.r.t the clinical trial supply market?
  2. As per reports, North America accounts for nearly 40 – 45 percent shares of the total CTS market.
  1. Why do major CROs, and different biopharmaceutical companies have their hubs in North America?
  2. Major CROs, biopharmaceutical companies, and clinical research organizations prefer having their hubs in North America because a high number of clinical trials are performed in these regions.
  1. Who are the main key suppliers of the clinical trial supply (CTS) market?
  2. According to the insights of Beroe’s report, the main suppliers of the CTS market are: Fisher Clinical Almac Multipharma Durbin Clinigen Group Catalent KLIFO A/S Zuellig Pharma ADAllen Myoderm
  1. What is the most preferred model for both engagement and pricing in the CTS market? What are the alternative models?
  2. The most preferred engagement model in the CTS market offering are alternatives like – preferred supplier, FSP, and strategic partnerships. Similarly, w.r.t pricing, the most preferred model is the unit-based pricing model offering an alternative to – project-based pricing.
  1. How can the pharma sector ensure the smooth running of clinical trials?
  2. Following the insights from Beroe’s report, the pharma sector can seamlessly run clinical trials by leveraging an import broker to overcome regional difficulties like compliance with import/export regulations for shipments of CTS.
  1. What are the main objectives undertaken by the European One Health Action Plan developed by EMA?
  2. EMA developed a new European One Health Action Plan against AMR to cater to initiatives like: Making the E.U. the best practice region when it comes to fighting Antimicrobial Resistance (AMR) growth Boosting research, development, and innovation Shaping the global agenda by making the E.U. more influential on AMR internationally
  1. What factor contributes to the increase in planning and sourcing of ancillary material within the clinical trial supplies market?
  2. As per Beroe, the globalization of clinical trials is encouraging pharma companies to conduct phase III clinical trials across different and fast-growing geographies namely, Eastern Europe, China, Korea, and Taiwan which is contributing to an increase in planning and sourcing ancillary materials.
  1.  
  2.  
  1.  
  2.  
  1.  
  2.  
  1.  
  2.  

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)